Page last updated: 2024-10-16

gamma-aminobutyric acid and Suicidal Ideation

gamma-aminobutyric acid has been researched along with Suicidal Ideation in 8 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.

Research Excerpts

Excerpt	Relevance	Reference
"We determined the gene expression of 32 markers of the pathways of the two main neurotransmitters of the PFC, gamma-aminobutyric acid (GABA) and l-glutamic acid (glutamate), by real-time quantitative PCR in human postmortem anterior cingulate cortex (ACC) and dorsolateral PFC (DLPFC) in elderly non-suicidal patients with major depressive disorder (MDD) or bipolar disorder (BD)."	3.78	Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. ( Bao, AM; Kamphuis, W; Lou, JS; Luchetti, S; Qi, XR; Swaab, DF; Zhao, J, 2012)
"Yet, migraine by itself is associated with an increased risk of suicidal ideation and behavior as well as with an increased risk of psychiatric disorders that facilitate the development of suicidal behavior."	2.47	Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? ( Kanner, AM, 2011)

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	7 (87.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Lybech, LKM	1
Calabró, M	1
Briuglia, S	1
Drago, A	1
Crisafulli, C	1
Allen, RP	1
Chen, C	1
Garcia-Borreguero, D	1
Polo, O	1
DuBrava, S	1
Miceli, J	1
Knapp, L	1
Winkelman, JW	1
Kalia, M	1
Costa E Silva, J	1
Yin, H	1
Pantazatos, SP	1
Galfalvy, H	1
Huang, YY	1
Rosoklija, GB	1
Dwork, AJ	1
Burke, A	1
Arango, V	1
Oquendo, MA	1
Mann, JJ	1
Setoyama, D	1
Kato, TA	1
Hashimoto, R	1
Kunugi, H	1
Hattori, K	1
Hayakawa, K	1
Sato-Kasai, M	1
Shimokawa, N	1
Kaneko, S	1
Yoshida, S	1
Goto, YI	1
Yasuda, Y	1
Yamamori, H	1
Ohgidani, M	1
Sagata, N	1
Miura, D	1
Kang, D	1
Kanba, S	1
Mutschler, J	1
Grosshans, M	1
Herwig, U	1
Heekeren, K	1
Kawohl, W	1
Brühl, A	1
Kanner, AM	1
Zhao, J	1
Bao, AM	1
Qi, XR	1
Kamphuis, W	1
Luchetti, S	1
Lou, JS	1
Swaab, DF	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome[NCT00806026]			Phase 3	731 participants (Actual)	Interventional	2008-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Limb Pain-VAS at Week 12

100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean. (NCT00806026)
Timeframe: Baseline, Week 12

Intervention	mm (Least Squares Mean)
Pregabalin 300 mg	-3.20
Pramipexole 0.25 mg	-2.64
Pramipexole 0.5 mg	-2.75
Placebo	-2.20

Change From Baseline in RLS-NDI at Week 12

The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact. (NCT00806026)
Timeframe: Baseline, Week 12

Intervention	Units on a Scale (Least Squares Mean)
Pregabalin 300 mg	-8.10
Pramipexole 0.25 mg	-4.30
Pramipexole 0.5 mg	-14.50
Placebo	-6.60

Change From Baseline in SSQ: Subjective WASO at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep. (NCT00806026)
Timeframe: Baseline, Week 12

Intervention	minutes (Least Squares Mean)
Pregabalin 300 mg	-49.86
Pramipexole 0.25 mg	-33.69
Pramipexole 0.5 mg	-37.18
Placebo	-32.61

Change From Baseline in the RLS Symptom Severity at Week 12

IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life. (NCT00806026)
Timeframe: Baseline, Week 12

Intervention	Units on a Scale (Least Squares Mean)
Pregabalin 300 mg	-11.80
Pramipexole 0.25 mg	-7.90
Pramipexole 0.5 mg	-10.50
Placebo	-7.30

Clinical Global Impressions-Severity (CGI-S) at Week 12

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected. (NCT00806026)
Timeframe: Week 12

Intervention	Units on a Scale (Mean)
Pregabalin 300 mg	2.90
Pramipexole 0.25 mg	3.50
Pramipexole 0.5 mg	3.10
Placebo	3.70

Limb Pain-Visual Analog Scale (Limb Pain-VAS)

100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. (NCT00806026)
Timeframe: Baseline

Intervention	mm (Mean)
Pregabalin 300 mg	4.20
Pramipexole 0.25 mg	4.30
Pramipexole 0.5 mg	4.00
Placebo	4.10

Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12

MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes. (NCT00806026)
Timeframe: Week 12

Intervention	Participants (Number)
Pregabalin 300 mg	84
Pramipexole 0.25 mg	64
Pramipexole 0.5 mg	77
Placebo	68

Percentage of Participants Responding to Treatment at Week 12

"CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of very much improved or much improved." (NCT00806026)
Timeframe: Week 12

Intervention	Percentage of participants (Number)
Pregabalin 300 mg	71.40
Pramipexole 0.25 mg	51.20
Pramipexole 0.5 mg	62.70
Placebo	46.80

Percentage of Participants With Augmentation

Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation. (NCT00806026)
Timeframe: Baseline up to Week 52

Intervention	Percentage of participants (Number)
Pregabalin 300 mg	1.70
Pramipexole 0.25 mg	6.60
Pramipexole 0.5 mg	9.00

Restless Legs Syndrome (RLS) Symptom Severity

International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life. (NCT00806026)
Timeframe: Baseline

Intervention	Units on a Scale (Mean)
Pregabalin 300 mg	22.30
Pramipexole 0.25 mg	22.40
Pramipexole 0.5 mg	22.10
Placebo	22.40

Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12

RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. (NCT00806026)
Timeframe: Week 12

Intervention	Units on Scale (Mean)
Pregabalin 300 mg	77.75
Pramipexole 0.25 mg	73.33
Pramipexole 0.5 mg	75.48
Placebo	73.23

RLS-Next Day Impact (RLS-NDI)

Intervention	Units on a Scale (Mean)
Pregabalin 300 mg	49.30
Pramipexole 0.25 mg	51.90
Pramipexole 0.5 mg	58.40
Placebo	50.00

Severity of Augmentation Symptoms at Week 12

ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation. (NCT00806026)
Timeframe: Week 12

Intervention	Units on a Scale (Mean)
Pregabalin 300 mg	0.90
Pramipexole 0.25 mg	1.60
Pramipexole 0.5 mg	1.30
Placebo	1.40

Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep. (NCT00806026)
Timeframe: Week 12

Intervention	hours (Mean)
Pregabalin 300 mg	7.00
Pramipexole 0.25 mg	6.70
Pramipexole 0.5 mg	6.80
Placebo	6.70

Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep. (NCT00806026)
Timeframe: Week 12

Intervention	minutes (Mean)
Pregabalin 300 mg	41.60
Pramipexole 0.25 mg	43.10
Pramipexole 0.5 mg	35.90
Placebo	47.70

Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep. (NCT00806026)
Timeframe: Week 12

Intervention	awakenings (Mean)
Pregabalin 300 mg	1.10
Pramipexole 0.25 mg	1.70
Pramipexole 0.5 mg	1.50
Placebo	1.80

Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep. (NCT00806026)
Timeframe: Week 12

Intervention	Units on a scale (Mean)
Pregabalin 300 mg	66.50
Pramipexole 0.25 mg	57.40
Pramipexole 0.5 mg	60.20
Placebo	57.70

Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)

Intervention	minutes (Mean)
Pregabalin 300 mg	90.60
Pramipexole 0.25 mg	100.20
Pramipexole 0.5 mg	83.90
Placebo	79.50

Medical Outcomes Study-Short Form 36 (SF-36) at Week 12

"SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from 0=much worse now to 4=much better now. Higher subscale and summary score reflect better health status." (NCT00806026)
Timeframe: Week 12

,,,

Intervention	Units on a Scale (Mean)
	Physical functioning	Role physical	Bodily pain	General health	Vitality	Social functioning	Role emotional	Mental health	Summary physical score	Summary mental score	Summary of health status
Placebo	83.00	81.50	65.50	72.80	59.30	86.80	87.00	78.70	75.70	78.00	3.10
Pramipexole 0.25 mg	81.90	79.60	65.20	69.80	59.00	84.50	83.90	74.60	74.20	75.50	3.10
Pramipexole 0.5 mg	82.40	79.10	69.00	70.50	59.80	84.00	84.60	76.10	75.30	76.10	3.20
Pregabalin 300 mg	83.70	81.20	73.30	73.60	62.40	87.20	85.10	77.40	78.00	78.00	3.10

Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12

MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes. (NCT00806026)
Timeframe: Week 12

,,,

Intervention	Units on a Scale (Mean)
	Sleep disturbance (n = 175, 169, 178, 171)	Snoring (n = 172, 169, 178, 170)	Awakening short of breath (n = 175, 169, 178, 171)	Sleep adequacy (n = 128, 120, 133, 125 )	Somnolence (n = 175, 169, 178, 171)	Sleep quantity (n = 175, 169, 178, 171)	Sleep problem index I (n = 175, 169, 178, 171)	Sleep problem index II (n = 175, 169, 178, 171)
Placebo	38.60	24.60	9.60	50.00	26.00	6.50	35.00	36.30
Pramipexole 0.25 mg	39.30	25.80	12.30	54.80	27.60	6.50	35.30	36.60
Pramipexole 0.5 mg	34.40	25.80	13.80	55.20	25.50	6.60	33.40	34.10
Pregabalin 300 mg	30.50	29.00	10.50	61.30	23.90	6.80	29.40	30.70

Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12

WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. (NCT00806026)
Timeframe: Week 12

,,,

Intervention	Percentage of impairment (Mean)
	Overall work (n= 10, 7, 11, 10)	Activity (n= 18, 22, 25, 20)	Work time missed (n= 10, 7, 11, 10)
Placebo	14.60	23.00	1.50
Pramipexole 0.25 mg	5.70	20.90	0.00
Pramipexole 0.5 mg	9.10	22.80	0.00
Pregabalin 300 mg	6.00	12.20	0.00

Reviews

2 reviews available for gamma-aminobutyric acid and Suicidal Ideation

Article	Year
Biomarkers of psychiatric diseases: current status and future prospects. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:3 Suppl 1 Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph	2015
Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? Current pain and headache reports, 2011, Volume: 15, Issue:3 Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Labeling; Fructose; Gabapentin; gamma-Ami	2011

Trials

1 trial available for gamma-aminobutyric acid and Suicidal Ideation

Article	Year
Comparison of pregabalin with pramipexole for restless legs syndrome. The New England journal of medicine, 2014, Feb-13, Volume: 370, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzothiazoles; Dopamine Agonists; Double-Blind Met	2014

Other Studies

5 other studies available for gamma-aminobutyric acid and Suicidal Ideation

Article	Year
Suicide Related Phenotypes in a Bipolar Sample: Genetic Underpinnings. Genes, 2021, 09-23, Volume: 12, Issue:10 Topics: Adult; Aged; Aminopeptidases; Bipolar Disorder; gamma-Aminobutyric Acid; Genetic Predisposition to D	2021
A pilot integrative genomics study of GABA and glutamate neurotransmitter systems in suicide, suicidal behavior, and major depressive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2016, Volume: 171B, Issue:3 Topics: Adult; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Gene Expression Regulation; Geno	2016
Plasma Metabolites Predict Severity of Depression and Suicidal Ideation in Psychiatric Patients-A Multicenter Pilot Analysis. PloS one, 2016, Volume: 11, Issue:12 Topics: 3-Hydroxybutyric Acid; Betaine; Biomarkers; Chromatography, Liquid; Citric Acid; Creatinine; Depress	2016
Pregabalin-induced suicidal ideations. Pharmacopsychiatry, 2011, Volume: 44, Issue:3 Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Pregabalin; Su	2011
Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. Journal of affective disorders, 2012, Volume: 138, Issue:3 Topics: Aged; Aged, 80 and over; Bipolar Disorder; Depressive Disorder, Major; Female; gamma-Aminobutyric Ac	2012